More study needed into the ‘why’ of new weight-loss drugs

Hitting the market over the past six years, the drugs Ozempic, Wegovy and Mounjaro are viewed as a therapeutic breakthrough for the 42% of the U.S. population who are clinically obese. However, more research is needed.

These drugs are not the be-all and end-all to weight-loss therapy, wrote Dr. Michael Schwartz in a commentary published Oct. 2 in The Journal of Clinical Investigation (co-author is postdoctoral fellow Dr. Sophie Yang Gou.)

Many experts seem to be saying “OK, we’ve fixed this problem. We’re done,” noted Schwartz, who co-directs the UW Medicine Diabetes Institute. That is simply not the case, he said.

Read the full story from UW Medicine Newsroom.